The Life Sciences Report

Other Streetwise Reports

The Gold Report The Energy Report The Life Sciences Report The Mining Report

Today's Featured Company

Rexahn Pharmaceuticals Inc.: (RNN:NYSE.MKT) Rexahn Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing best-in-class therapeutics for the treatment of cancer. The company's cancer drugs have been shown to directly target cancer cells while bypassing healthy cells, demonstrating increased efficacy and reduced toxicity. These drug candidates are effective against multiple drug-resistant cancers and show they can work together with FDA-approved cancer treatments to increase efficacy. More >

Streetwise Expert Interviews

Four Hidden Australian Life Sciences Growth Stocks Revealed: Scott Power

To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement. (4/17/14) More >

Newsletter Briefs

"RXII has some very important valuation-driving events in progress." (4/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey More >

"ARNI's chairman is one of the best in the world in the urology field, and the company's consortium of investors has given us a lot of validation." (4/3/14) Arno Therapeutics Inc. - The Life Sciences Report Interview with Ran Nussbaum More >

"ATHX's MultiStem has the potential to completely change existing treatment paradigms." (4/2/14) Athersys Inc. - Jason Kolbert, Maxim Group More >

"Our price target on DMPI represents 294% upside potential." (3/31/14) DelMar Pharmaceuticals Inc. - SeeThruEquity More >

"We believe AMBS' MANF molecule is one of the jewels in the field." (3/26/14) Amarantus BioScience Holdings Inc. - The Life Sciences Report Interview with David Lowe More >

"NBS increased its operating margin and lowered its production cost." (3/25/14) NeoStem Inc. - Shawn Arshad, Seeking Alpha More >

"BLU presented to our advisory board and came out as one of the favorites." (3/19/14) BELLUS Health Inc. - The Life Sciences Report Interview with Hugh Cleland More >

"Positive clinical data will make CTH's APL-130277 a very attractive asset for specialty pharma or large pharma." (3/19/14) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Stephen Ireland More >

Expert Analysis

"CYTX's corporate direction will not change with the new CEO." (4/3/14) Cytori Therapeutics Inc. - Yale Jen, Laidlaw & Company More >

"We are initiating coverage on DMPI with a Buy rating." (4/2/14) DelMar Pharmaceuticals Inc. - Jason Kolbert, Maxim Group More >

"OPK launched 4KScore in the U.S. as a test for prostate cancer." (4/1/14) OPKO Health Inc. - Kevin DeGeeter, Ladenburg Thalmann More >

"BFLS' offering opened at $4.30, down from $5.24; do the math, Buy!" (3/26/14) BioLife Solutions Inc. - Henry McCusker, Scimitar Equity LLC More >

"Gross margins for CGIX's base business could double in 18–24 months." (3/27/14) Cancer Genetics Inc. - Raghuram Selvaraju, Aegis Capital Corp. More >

"Our price target on DMPI represents 294% upside potential." (3/31/14) DelMar Pharmaceuticals Inc. - SeeThruEquity More >

"Interim results showed increased blood concentration of CTH's drug." (3/31/14) Cynapsus Therapeutics Inc. - Jerry Isaacson, LifeSci Advisors More >

"BFLS' contract manufacturing business is expected to provide a source of near-term revenue and cash flow." (3/31/14) BioLife Solutions Inc. - Brian Marckx, Zacks Investment Research More >